Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 29;44(1):144.
doi: 10.1186/s13052-018-0584-8.

Off-label drugs use in pediatric palliative care

Lucia De Zen  1 , Federico Marchetti  2 , Egidio Barbi  3   4 , Franca Benini  5
Affiliations

Off-label drugs use in pediatric palliative care

Lucia De Zen et al. Ital J Pediatr. .

Abstract

Background: Paediatric palliative care (PPC) aim to ensure the control of symptoms and the best possible quality of life for patients whose underlying disease, characterized by an unstoppable evolution and negative prognosis, no longer responds to specific treatments. The scientific evidence in this context are very deficient and, in order to obtain welfare objectives consistent with the situation, in the overwhelming majority of cases the prescription of drugs is off-label for indication of use and/or for age and/or for way of administration and/or formulation. The Agenzia Italiana del Farmaco - AIFA and the Italian Society of Palliative Care (Società Italiana di Cure Palliative - SICP), under a dedicated working group, wrote a document that collects the scientific evidence available to support the off-label use of medicines more frequently used in PPC. The goal is to certify the consolidated off-label use of these drugs and propose their use under the Law 648/96, in the absence of data from its pivotal clinical trials. Aim of the commentary is to report the conditions for this important work and to present the 10 drugs, usually used off-label in PPC and in pain therapy, now included in Law 648/96.

Conclusion: This work is deemed essential to resolve, at least in part, the lack of availability of medicines researched and approved.

Keywords: Off-label drugs; Pain; Pediatric palliative care.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. European Union. Regulation (EC) N° 1901/2006 on Medicinal Products for Paediatric Use and Amending Regulation (EEC) N° 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) N° 726/2004. Available at: http://ec.europa.eu/health/human-use/paediatric-medicines/index_en.htmORhttp://eur-lex.europa.eu/RECH_legislation.do.
    1. European Medicines Agency. Updated priority list (revised) for studies into off-patent paediatric medicinal products. Doc. Ref. EMA/197972/2007. London: EMA, 2007.
    1. Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr. 2005;164(9):552–558. doi: 10.1007/s00431-005-1698-8. - DOI - PubMed
    1. Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf. 2006;5(5):703–718. 2. doi: 10.1517/14740338.5.5.703. - DOI - PubMed
    1. Gore R, Chugh PK, Tripathi CD, Lhamo Y, Gautam S. Pediatric off-label and unlicensed drug use and its implications. Curr Clin Pharmacol. 2017;12(1):18–25. doi: 10.2174/1574884712666170317161935. - DOI - PubMed